{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-059364","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.145904+00:00","generated_at":"2026-06-05T04:12:01.509490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IO Biotech Q4 net loss $26.2M; Phase 3 melanoma trial enrollment complete, interim ORR analysis expected Q3 2024","bullets":["Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.","Cash $143.2M at Dec 31, 2023; operational runway projected into Q4 2025.","Completed enrollment of 380 patients in pivotal Phase 3 trial of IO102-IO103 + Keytruda in advanced melanoma.","Planned interim ORR analysis from first 225 patients expected in Q3 2024; PFS primary endpoint anticipated H2 2025.","First patient dosed in Phase 2 basket trial of IO102-IO103 neoadjuvant/adjuvant in resectable solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-059364","json":"https://secwatch.observer/filing/0001193125-24-059364.json","markdown":"https://secwatch.observer/filing/0001193125-24-059364.md","text":"https://secwatch.observer/filing/0001193125-24-059364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/0001193125-24-059364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/d747385d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:12:01.509490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14ba7da5ed5259e470318b32c937a9e2b4532403","claim":"IO Biotech, Inc. reported three months ended December 31, 2023 results: net income $26.2 million.","evidence_excerpt":"Net loss for the three months ended December 31, 2023, was $26.2 million, compared to $20.1 million for the three months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/0001193125-24-059364-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Net income","value":"$26.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}